Physician profile
Jeray J Johnson
NPI 1629181706
$3,752.29
in general payments reported to CMS, 2019-2025
13 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,143 · 2021: $32.48 · 2023: $102 · 2024: $289 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,165.30 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Philips North America LLC | $146.18 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $140.66 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Insmed, INC. | $94.94 | 2021-2024 | Arikayce |
| Verona Pharma, INC. | $47.20 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $42.64 | 2024 | Yupelri |
| Amgen INC. | $19.21 | 2024 | Otezla, Repatha |
| Avadel Cns Pharmaceuticals, LLC | $18.57 | 2024 | Lumryz |
| Baxter Healthcare | $17.39 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Paratek Pharmaceuticals, INC. | $16.09 | 2023 | Nuzyra |
| Viatris Specialty LLC | $15.63 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2024 | Glassia |
| Genentech USA, INC. | $13.54 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeray Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.